ClinVar Miner

Submissions for variant NM_001042492.3(NF1):c.7971-19G>T

gnomAD frequency: 0.01950  dbSNP: rs17887156
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
PreventionGenetics, part of Exact Sciences RCV000249320 SCV000306299 benign not specified criteria provided, single submitter clinical testing
GeneDx RCV000587114 SCV000518975 benign not provided 2016-04-05 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000587114 SCV000604519 benign not provided 2023-09-27 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000587114 SCV000696408 benign not provided 2016-05-12 criteria provided, single submitter clinical testing Variant summary: The NF1 c.7908-19G>T variant involves the alteration of a non-conserved intronic nucleotide with 5/5 splice prediction tools calculating no significant effect on splicing, although these predictions have yet to be functionally assessed. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 699/109636 (21 homozygotes, 1/156, frequency: 0.0063756), predominantly observed in the African cohort, 660/9614 (21 homozygotes, 1/14, frequency: 0.06865), which significantly exceeds the estimated maximal expected allele frequency for a pathogenic NF1 variant of 1/4798 (0.0002084). Therefore, suggesting the variant is a common polymorphism found in population(s) of African origin. The variant of interest, to our knowledge, has not been reported in affected individuals via publications and/or reputable databases/clinical laboratories. Therefore, taking all available lines of evidence into consideration, the variant of interest is classified as Benign.
Labcorp Genetics (formerly Invitae), Labcorp RCV002057433 SCV002457081 benign Neurofibromatosis, type 1 2025-02-04 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV002057433 SCV002561339 benign Neurofibromatosis, type 1 2022-03-15 criteria provided, single submitter clinical testing
KCCC/NGS Laboratory, Kuwait Cancer Control Center RCV003316372 SCV004016407 benign Neurofibromatosis, familial spinal 2023-07-07 criteria provided, single submitter clinical testing
Genome Diagnostics Laboratory, Amsterdam University Medical Center RCV000249320 SCV001807122 benign not specified no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000249320 SCV001965216 benign not specified no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.